Review: Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs

Arthritis and Rheumatism

Volumn 40, Issue 2, 1997, Pages 201-208

  Walker, Alexander M ^a,b  

^a Epidemiology Resources Inc   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; FENBUFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

DRUG USE; HUMAN; INCIDENCE; LIVER INJURY; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STATISTICAL ANALYSIS; CHEMICALLY INDUCED DISORDER; LIVER DISEASE; RISK FACTOR;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; INCIDENCE; LIVER DISEASES; RISK FACTORS;

EID: 0030614703     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400204     Document Type: Review

References (11)

1. Walker AM, Cavanaugh RJ: The occurrence of new hepatic disorders in a defined population. Post Marketing Surveillance 6:107-117, 1992
2. Zimmerman HJ: Update of hepatotoxicity due to classes of drugs in common clinical use: non-steroidal drugs, anti-inflammatory drugs, antibiotics, antihypertensives, and cardiac and psychotropic drugs. Semin Liver Dis 10:322-338, 1990
3. Strom BL, Carson JL, Morse ML, Leroy M: The computerized on-line medical pharmaceutical analysis and surveillance system: a new resource for post-marketing drug surveillance. Clin Pharmacol Ther 38:359-364, 1985
4. Lanza LL, Dreyer NA, Schultz NJ, Walker AM: Use of insurance claims in epidemiologic research: identification of peptic ulcers, GI bleeding, pancreatitis, hepatitis, and renal disease. Pharmacoepidemiology Drug Safety 4:239-248, 1995
5. García Rodríguez LA, Pérez Gutthann S, Walker AM, Lueck L: The role of non-steroidal anti-inflammatory drugs in acute liver injury. BMJ 305:865-868, 1992
6. Pérez Gutthann S, García Rodríguez LA: The increased risk of hospitalizations for acute liver injury in a population with exposure to multiple drugs. Epidemiology 4:496-501, 1993
7. Carson JL, Strom BL, Duff A, Gupta A, Das K: Safety of nonsteroidal anti-inflammatory drugs with respect to acute liver disease. Arch Intern Med 153:1331-1336, 1993
8. Lanza LL, Walker AM, Bortnichak EA, Gause DO, Dreyer NA: Incidence of symptomatic liver function abnormalities in a cohort of NSAID users. Pharmacoepidemiology Drug Safety 4:231-237, 1995
9. Garcia Rodríguez LA, Williams R, Derby LE, Dean AD, Jick H: Acute liver injury associated with nonsteroidal anti-inflammatory drugs and the role of risk factors. Arch Intern Med 154:311-316, 1994
10. Walker AM, Bortnichak EA, Lanza LL, Yood RA: The infrequcncy of liver function testing in patients using non-steroidal anti-inflammatory drugs. Arch Fam Med 4:24-29, 1995
11. Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J: Diclofenac associated hepatotoxicity, JAMA 264:2660-2666, 1990